We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Acadia Pharmaceuticals Inc (ACAD) Com Stk USD0.0001

Sell:$16.87 Buy:$16.89 Change: $0.14 (0.84%)
NASDAQ:1.03%
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$16.87
Buy:$16.89
Change: $0.14 (0.84%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$16.87
Buy:$16.89
Change: $0.14 (0.84%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

Contact details

Address:
12830 El Camino Real, Suite 400
SAN DIEGO
92130
United States
Telephone:
+1 (858) 5582871
Website:
https://acadia.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ACAD
ISIN:
US0042251084
Market cap:
$2.81 billion
Shares in issue:
166.39 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Catherine Owen Adams
    Chief Executive Officer, Director
  • Mark Schneyer
    Chief Financial Officer, Executive Vice President
  • Jennifer Rhodes
    Executive Vice President, Company Secretary and Chief Legal Officer
  • Elizabeth Thompson
    Executive Vice President and Head of Research and Development
  • Albert Kildani
    Senior Vice President, Investor Relations and Corporate Communications
  • Kevin Oliver
    Senior Vice President, Chief Business Officer
  • Holly Valdiviez
    Senior Vice President - Neuropsychiatric Franchise
  • Thomas Garner
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.